Annals of Oncology

in this issue
pp. 181-181(1)

Non-adherence to endocrine therapy for breast cancer
pp. 183-184(2)
Author: Partridge, A. H.

On prejudice and facts and choices
pp. 185-187(3)
Authors: Köhne, C.-H.; Folprecht, G.

The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review
pp. 189-199(11)
Authors: Stefanidis, D.; Grove, K. D.; Schwesinger, W. H.; Thomas, C. R.

Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
pp. 200-204(5)
Authors: Vergote, I.; Abram, P.

Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
pp. 205-210(6)
Authors: Fallowfield, L.; Atkins, L.; Catt, S.; Cox, A.; Coxon, C.; Langridge, C.; Morris, R.; Price, M.

Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the `Observatory on Elderly Patients'
pp. 211-216(6)
Authors: Freyer, G.; Braud, A.-C.; Chaibi, P.; Spielmann, M.; Martin, J.-P.; Vilela, G.; Guerin, D.; Zelek, L.

Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
pp. 217-225(9)
Authors: Lønning, P. E.

A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
pp. 226-231(6)
Authors: Ma, C. X.; Steen, P.; Rowland, K. M.; Niedringhaus, R. D.; Fitch, T. R.; Kugler, J. W.; Hillman, D. W.; Perez, E. A.; Ingle, J. N.; Adjei, A. A.

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
pp. 232-238(7)
Authors: Colleoni, M.; Orlando, L.; Sanna, G.; Rocca, A.; Maisonneuve, P.; Peruzzotti, G.; Ghisini, R.; Sandri, M. T.; Zorzino, L.; Nolè, F.; Viale, G.; Goldhirsch, A.

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
pp. 239-245(7)
Authors: Twelves, C.; Gollins, S.; Grieve, R.; Samuel, L.

Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study
pp. 246-251(6)
Authors: De Paoli, A.; Chiara, S.; Luppi, G.; Friso, M. L.; Beretta, G. D.; Del Prete, S.; Pasetto, L.; Santantonio, M.; Sarti, E.; Mantello, G.; Innocente, R.; Frustaci, S.; Corvò, R.; Rosso, R.

Short-time infusion of oxaliplatin in combination with capecitabine (XELOX₃₀) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
pp. 252-258(7)
Authors: Pfeiffer, P.; Sørbye, H.; Ehrsson, H.; Fokstuen, T.; Mortensen, J. P.; Baltesgard, L.; Tveit, K. M.; Øgreid, D.; Starkhammar, H.; Wallin, I.; Qvortrup, C.; Glimelius, B.

Hypersensitivity reactions to oxaliplatin: experience in a single institute
pp. 259-261(3)
Authors: Siu, S. W. K.; Chan, R. T. T.; Au, G. K. H.

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
pp. 262-269(8)
Authors: Nitti, D.; Wils, J.; Dos Santos, J. Guimaraes; Fountzilas, G.; Conte, P. F.; Sava, C.; Tres, A.; Coombes, R. C.; Crivellari, D.; Marchet, A.; Sanchez, E.; Bliss, J. M.; Homewood, J.; Couvreur, M. L.; Hall, E.; Baron, B.; Woods, E.; Emson, M.; Van Cutsem, E.; Lise, M.

A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial
pp. 270-275(6)
Authors: O'Brien, M. E. R.; Watkins, D.; Ryan, C.; Priest, K.; Corbishley, C.; Norton, A.; Ashley, S.; Rowell, N.; Sayer, R.

Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG)
pp. 276-280(5)
Authors: Krege, S.; Boergermann, C.; Baschek, R.; Hinke, A.; Pottek, T.; Kliesch, S.; Dieckmann, K.-P.; Albers, P.; Knutzen, B.; Weinknecht, S.; Schmoll, H.-J.; Beyer, J.; Ruebben, H.

Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon
pp. 281-285(5)
Authors: Latagliata, R.; Bongarzoni, V.; Carmosino, I.; Mengarelli, A.; Breccia, M.; Borza, P. A.; D'Andrea, M.; D'Elia, G. M.; Mecarocci, S.; Morano, S. G.; Petti, M. C.; Mandelli, F.; Alimena, G.

Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy
pp. 286-288(3)
Authors: Avilés, A.; Neri, N.; Nambo, M. J.

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
pp. 289-296(8)
Authors: Karthaus, M.; Kretzschmar, A.; Kröning, H.; Biakhov, M.; Irwin, D.; Marschner, N.; Slabber, C.; Fountzilas, G.; Garin, A.; Abecasis, N. G. F.; Baronius, W.; Steger, G. G.; Südhoff, T.; Giorgetti, C.; Reichardt, P.

Risk factors for venous thromboembolic events in cancer patients
pp. 297-303(7)
Authors: Kröger, K.; Weiland, D.; Ose, C.; Neumann, N.; Weiss, S.; Hirsch, C.; Urbanski, K.; Seeber, S.; Scheulen, M. E.

Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
pp. 304-312(9)
Authors: Steel, J. L.; Eton, D. T.; Cella, D.; Olek, M. C.; Carr, B. I.

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer
pp. 313-321(9)
Authors: Mita, M. M.; Ochoa, L.; Rowinsky, E. K.; Kuhn, J.; Schwartz, G.; Hammond, L. A.; Patnaik, A.; Yeh, I.-T.; Izbicka, E.; Berg, K.; Tolcher, A. W.

Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
pp. 322-329(8)
Authors: Nolè, F.; Catania, C.; Sanna, G.; Imadalou, K.; Munzone, E.; Adamoli, L.; Longerey, B.; Blanchot, G.; Goldhirsch, A.

Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
pp. 330-333(4)
Authors: Ogawa, Y.; Hotta, T.; Tobinai, K.; Watanabe, T.; Sasaki, Y.; Minami, H.; Morishima, Y.; Ogura, M.; Seriu, T.

Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study
pp. 334-340(7)
Authors: Hotte, S. J.; Oza, A.; Winquist, E. W.; Moore, M.; Chen, E. X.; Brown, S.; Pond, G. R.; Dancey, J. E.; Hirte, H. W.

Consumption of sweet foods and breast cancer risk in Italy
pp. 341-345(5)
Authors: Tavani, A.; Giordano, L.; Gallus, S.; Talamini, R.; Franceschi, S.; Giacosa, A.; Montella, M.; La Vecchia, C.

Effects of new smoking regulations in Italy
pp. 346-347(2)
Authors: Gallus, S.; Zuccaro, P.; Colombo, P.; Apolone, G.; Pacifici, R.; Garattini, S.; La Vecchia, C.

Is it time to discontinue using high-dose chemotherapy for salvage of patients with advanced germ-cell tumors failing first-line platinum chemotherapy?
pp. 349-350(2)
Authors: Oyan, B.; Koc, Y.

Comment on `Jaw avascular bone necrosis associated with long-term use of biphosphonates'
pp. 350-352(3)
Authors: Errante, D.; Mannucci, N.; Bernardi, D.; Bianco, A.; Salvagno, L.

Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention
pp. 350-350(1)
Authors: Christodoulou, C.; Tsakalos, G.; Galani, E.; Skarlos, D. V.

Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy
pp. 352-353(2)
Authors: Bogaerts, J.; Sylvester, R.; Therasse, P.

Chemotherapy-induced amenorrhea in early breast cancer
pp. 352-352(1)
Authors: Ferretti, G.; Carlini, P.; Bria, E.; Felici, A.; Giannarelli, D.; Ciccarese, M.; Papaldo, P.; Fabi, A.; Cognetti, F.

Response to letter “Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy” by Bogaerts et al. (Ann Oncol 2006; 17: 352–353)
pp. 353-354(2)
Authors: Cleator, S.; Makris, A.; Powles, T.